Gut microbiota-derived metabolite trimethylamine N-oxide as a biomarker in early Parkinson's disease

This study aimed to investigate the potential of using changes in the plasma levels of trimethylamine N-oxide (TMAO), a gut microbiota-derived metabolite, as a biomarker in early Parkinson's disease (PD). Plasma TMAO levels were measured in 85 patients with drug-naïve early stage PD and 20 heal...

Full description

Saved in:
Bibliographic Details
Published in:Nutrition (Burbank, Los Angeles County, Calif.) Los Angeles County, Calif.), 2021-03, Vol.83, p.111090-111090, Article 111090
Main Authors: Chung, Seok Jong, Rim, John Hoon, Ji, Dajeong, Lee, Sangwon, Yoo, Han Soo, Jung, Jin Ho, Baik, KyoungWon, Choi, Yonghoon, Ye, Byoung Seok, Sohn, Young H., Yun, Mijin, Lee, Sang-Guk, Lee, Phil Hyu
Format: Article
Language:English
Subjects:
Activities of daily living
Alzheimer's disease
Biomarkers
Brain research
Chromatography
Confidence intervals
Conversion
Dementia
Dementia disorders
Drug dosages
Gut microbiota
Intestinal microflora
Levodopa
Mass spectrometry
Medical prognosis
Metabolites
Microbiota
Movement disorders
Neurodegeneration
Neurodegenerative diseases
Outpatient care facilities
Parkinson's disease
Pathogenesis
Plasma
Plasma levels
Prognosis
Regression analysis
Regression models
Risk
Scientific imaging
Software
Statistical analysis
Subgroups
Trimethylamine
Trimethylamine N-oxide (TMAO)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study aimed to investigate the potential of using changes in the plasma levels of trimethylamine N-oxide (TMAO), a gut microbiota-derived metabolite, as a biomarker in early Parkinson's disease (PD). Plasma TMAO levels were measured in 85 patients with drug-naïve early stage PD and 20 healthy controls. A linear mixed model was used to assess longitudinal changes in levodopa-equivalent dose (LED) during follow-up (>2 y) in three tertile PD groups according to plasma TMAO levels. Additionally, a Cox regression analysis was performed to assess the effect of plasma TMAO levels on dementia conversion. Plasma TMAO levels of patients with PD were lower than those of healthy controls. A linear mixed model demonstrated that patients with PD and lower levels of TMAO (
ISSN:0899-9007
1873-1244
DOI:10.1016/j.nut.2020.111090